| Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy T Orban, K Farkas, H Jalahej, J Kis, A Treszl, B Falk, H Reijonen, ... Journal of autoimmunity 34 (4), 408-415, 2010 | 139 | 2010 |
| Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus J Kis, P Engelmann, K Farkas, G Richman, S Eck, J Lolley, H Jalahej, ... Journal of Leucocyte Biology 81 (3), 654-662, 2007 | 73 | 2007 |
| Reduced CD4+ T-cell-specific gene expression in human type 1 diabetes mellitus T Orban, J Kis, L Szereday, P Engelmann, K Farkas, H Jalahej, A Treszl Journal of autoimmunity 28 (4), 177-187, 2007 | 60 | 2007 |
| Characterization of human invariant natural killer T cells expressing FoxP3 P Engelmann, K Farkas, J Kis, G Richman, Z Zhang, CW Liew, ... International Immunology 23 (8), 473-484, 2011 | 28 | 2011 |
| Effectiveness of iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide, in people with type 2 diabetes JT Kis, G Nagy, G Kovacs Diabetes Therapy 12 (9), 2517-2529, 2021 | 16 | 2021 |
| Prevention of type 1 diabetes mellitus using a novel vaccine T Orban, JT Kis Therapeutic advances in endocrinology and metabolism 2 (1), 9-16, 2011 | 13 | 2011 |
| iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis … C Guja, JT Kis, M Haluzík, M Bonnemaire, G Bigot, M Tournay, ... Diabetes, Obesity and Metabolism 25 (6), 1723-1730, 2023 | 5 | 2023 |
| Effectiveness and safety of iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) in type 2 diabetes according to the timing of daily administration: data from the REALI … M Haluzík, J Seufert, C Guja, M Bonnemaire, G Bigot, M Tournay, JT Kis, ... Diabetes Therapy 14 (4), 639-652, 2023 | 4 | 2023 |
| Network analysis of neurotransmitter related human kinase genes. Possible role of SRC, RAF1, PTK2B? Z BRyS, A Pluhar, JT Kis, B Buda, A Szabo Neuropsychopharmacologia Hungarica 15 (3), 165-171, 2013 | 4 | 2013 |
| Kettős inkretinterápia–új lehetőség a 2-es típusú diabetes vércukorcsökkentő kezelésében= Dual incretin therapy–a novel approach in the antidiabetic therapy of type 2 diabetes G Winkler, JT Kis, L Schandl LEGE ARTIS MEDICINAE 32 (6-7), 247-253, 2022 | 3 | 2022 |
| Glucagon-like peptide-1 (GLP1) and the gastrointestinal tract. GLP1 receptor agonists: overemphasized gastric, forgotten intestinal ("ileal brake") effect? G Winkler, P Hajos, JT Kiss Orvosi Hetilap 160 (49), 1927-1934, 2019 | 3 | 2019 |
| The" other" incretin-the therapeutic rediscovery of the glucose-dependent insulinotropic polypeptide G Winkler, JT Kis, L Schandl Orvosi Hetilap 164 (6), 210-218, 2023 | 2 | 2023 |
| Indokolt-e a klasszifikáció módosítása diabetesben? G Winkler, JT Kis, L Schandl Orvosi Hetilap 163 (48), 1909-1916, 2022 | 2 | 2022 |
| Immunologic prevention in type 1 diabetes mellitus J Kis, P Engelmann, H Jalahei, T Orban Lege Artis Medicinæ 16 (8/9), 771, 2006 | 2 | 2006 |
| Inzulinpumpa-kezelés 1-es típusú diabetes mellitusban JT KIS, L KAUTZKY, A GROSZ LAM Lege Artis Medicinae 2009; 19 (10): 583 6, 0 | 2 | |
| From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism. G Winkler, JT Kis, L Schandl Orvosi Hetilap 164 (42), 1656-1664, 2023 | 1 | 2023 |
| 637-P: effectiveness of fixed ratio combination of IGlarLixi in people with type 2 diabetes mellitus: experience from routine clinical practice JT Kis, G Nagy, P Stella Diabetes 70 (Supplement_1), 2021 | 1 | 2021 |
| Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use J Seufert, N Freemantle, C Guja, M Haluzík, M Tournay, C Vera, ... Diabetes, Obesity and Metabolism 26 (7), 2988-2992, 2024 | | 2024 |
| A Hungarian Centrum Hospital’s COVID-19 Response Strategy in Light of International Management Experiences L Schandl, B Kiss, Z Lengyel, JT Kis, G Winkler COVID 4 (6), 815-824, 2024 | | 2024 |
| 786-P: Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) according to Baseline BMI JT KIS, J SEUFERT, M HALUZIK, C VERA, M TOURNAY, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
Tihamer Orban在 bwh.harvard.edu 的电子邮件经过验证
